Catalyst
Slingshot members are tracking this event:
FDA grants breakthrough therapy designation for Roche’s (RHHBY) Actemra/RoActemra in giant cell arteritis, a form of vasculitis
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| RHHBY |
|
|
||||
Additional Information
In June this year, Roche announced the positive outcome of the Phase III GiACTA study evaluating Actemra/RoActemra in people with GCA. Results showed that Actemra/RoActemra, initially combined with a six month steroid (glucocorticoid) regimen, more effectively sustained remission through one year compared to a six or 12 month steroid-only regimen in people with GCA. Full data will be presented at an upcoming medical meeting in 2016.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 05, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Actemra, Roactemra, Giant Cell Arteritis, Vasculitis
